Apr 9 |
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
|
Apr 9 |
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
|
Apr 9 |
11 Best Biotech ETFs To Buy
|
Apr 9 |
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
|
Apr 5 |
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
|
Apr 4 |
3 Underappreciated Healthcare Stocks to Buy Now: April 2024
|
Apr 3 |
Vertex Is Worth Your Attention
|
Apr 2 |
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
|
Apr 1 |
Vertex's NDS for its sickle cell disease and thalassemia treatment accepted for priority review by Health Canada
|
Apr 1 |
Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
|